SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sjöström Anne Christine)
 

Sökning: WFRF:(Sjöström Anne Christine) > (2020-2022) > Apomorphine formula...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006682naa a2200565 4500
001oai:researchportal.hkr.se/admin:publications/c6d20536-28ed-40b7-8f24-00ed69c4a3bb
003SwePub
008240621s2020 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:144085273
009oai:DiVA.org:liu-174324
0247 a oai:researchportal.hkr.se/admin:publications/c6d20536-28ed-40b7-8f24-00ed69c4a3bb2 URI
0247 a https://doi.org/10.1007/s00415-020-10031-12 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1440852732 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1743242 URI
040 a (SwePub)hkrd (SwePub)kid (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Hagell, Peteru Patient Reported Outcomes - Clinical Assessment Research and Education (PROCARE),Department of Nursing and Integrated Health Sciences,Avdelningen för sjuksköterskeutbildningarna och integrerad hälsovetenskap,The PRO-CARE Group, Faculty of Health Sciences, Kristianstad University, 291 88, Kristianstad, Sweden4 aut
2451 0a Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
264 c 2020-07-01
264 1b D. Steinkopff-Verlag,c 2020
300 a 6
500 a Funding agencies: Open access funding provided by Kristianstad University; Pharmaceuticals Sales andDevelopment Sweden AB.
520 a Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng
653 a Apomorphine; Complications; Nodules; Parkinson’s disease; Safety; Skin
7001 a Höglund, Arjau Karolinska Institutet,Department of Neurology, Karolinska University Hospital, Stockholm, Sweden,Karolinska University Hospital,Karolinska Universitetssjukhuset4 aut
7001 a Hellqvist, Carina,d 1976-u Linköpings universitet,Avdelningen för omvårdnad och reproduktiv hälsa,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linköping University Hospital,Universitetssjukhuset i Linköping4 aut0 (Swepub:liu)carhe89
7001 a Johansson, Eva-Lenau Karlstad Central Hospital,Centralsjukhuset Karlstad,Department of Neurology, Karlstad Central Hospital, Karlstad, Sweden4 aut
7001 a Löwed, Beritu Karlstad Central Hospital,Centralsjukhuset Karlstad,Department of Neurology, Karlstad Central Hospital, Karlstad, Sweden4 aut
7001 a Sjöström, Anne-Christineu Sahlgrenska University Hospital,Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden4 aut
7001 a Karlberg, Carinau Sahlgrenska University Hospital,Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden4 aut
7001 a Lundgren, Margarethu Karolinska University Hospital,Karolinska Universitetssjukhuset,Department of Neurology, Karolinska University Hospital, Stockholm, Sweden4 aut
7001 a Dizdar, Nil,d 1960-u Linköpings universitet,Avdelningen för neurobiologi,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linköping University4 aut0 (Swepub:liu)nildi39
7001 a Johansson, Andersu Karolinska Institutet,Department of Neurology, Karolinska University Hospital, Stockholm, Sweden,Karolinska University Hospital,Karolinska Universitetssjukhuset4 aut
7001 a Willows, Thomasu Karolinska University Hospital,Karolinska Universitetssjukhuset,Department of Neurology, Karolinska University Hospital, Stockholm, Sweden4 aut
7001 a Rådberg, Johanu Karlstad Central Hospital,Centralsjukhuset Karlstad,Department of Neurology, Karlstad Central Hospital, Karlstad, Sweden4 aut
7001 a Bergquist, Filipu Sahlgrenska University Hospital,Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden4 aut
7102 a Patient Reported Outcomes - Clinical Assessment Research and Education (PROCARE)b Department of Nursing and Integrated Health Sciences4 org
7730 t Journal of Neurologyd : D. Steinkopff-Verlagg 267:11, s. 3411-3417q 267:11<3411-3417x 0340-5354x 1432-1459
8564 u https://doi.org/10.1007/s00415-020-10031-1x freey FULLTEXT
8564 u https://link.springer.com/content/pdf/10.1007/s00415-020-10031-1.pdf
8564 u https://liu.diva-portal.org/smash/get/diva2:1538320/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u oai:researchportal.hkr.se/admin:publications/c6d20536-28ed-40b7-8f24-00ed69c4a3bb
8564 8u https://doi.org/10.1007/s00415-020-10031-1
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:144085273
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-174324

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy